Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

27%

4 of 15 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

9(52.9%)

Phase 3

4(23.5%)

Phase 4

2(11.8%)

Phase 2

2(11.8%)

17Total

Phase 1(9)

Phase 3(4)

Phase 4(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT06088784Phase 1Completed

A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants

Role: lead

NCT01568489Phase 2Completed

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Role: lead

NCT01194037Phase 1Completed

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Role: lead

NCT01806311Phase 1Completed

Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg

Role: lead

NCT06926933Phase 4Recruiting

Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

Role: lead

NCT02988362Phase 1Completed

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Role: lead

NCT06400589Phase 3Suspended

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Role: lead

NCT03334539Phase 2Completed

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

Role: lead

NCT05109702Phase 3Completed

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

Role: lead

NCT03846453Phase 3Completed

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

Role: lead

NCT04037488Unknown

Changes in Body Composition With Patients Under Androgen Deprivation Therapy

Role: collaborator

NCT02717208Phase 1Completed

Phase 1 Study for Safety and Tolerability of HL036

Role: lead

NCT01511874Phase 4Completed

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

Role: lead

NCT01541943Phase 3Completed

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

Role: lead

NCT01806363Phase 1Completed

Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

Role: lead

NCT01806324Phase 1Completed

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

Role: lead

NCT01440686Phase 1Completed

Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

Role: lead

NCT01232036Phase 1Completed

Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018

Role: collaborator

All 18 trials loaded